Tyra Biosciences

#Pharmachon 2024 is a wrap! We were pleased to highlight our newest research on TYRA-300 in HCH, while collaborating with industry colleagues, patient advocates and scientific leaders in the field of skeletal dysplasias. Looking forward to next year! More details here: https://bit.ly/45PoO4k

Today, we announced preclinical proof-of-concept results with TYRA-300, an investigational oral FGFR3 selective inhibitor, in hypochondroplasia (HCH). Learn more here: https://bit.ly/3RSPU4C  

We are pleased to introduce our Senior Vice President of Human Resources, Liz Pagano! Liz is a results-oriented leader who brings over 25 years of experience to TYRA, with a wealth of expertise in team building, culture creation and growth strategies. Join us in welcoming Liz! #biotech #leadership  

At #ICCBH2024 today, we showcased preclinical data in achondroplasia on our oral, FGFR3-selective inhibitor, TYRA-300, during an oral presentation.  This meeting brings together scientists and clinicians from across the globe to gain a better understanding of the growing skeleton in health and disease. We were thrilled to participate, and we thank the conference organizers for highlighting our scientific research in achondroplasia.  More details here: https://bit.ly/4cB3WQo #ICCBH2024 #achondroplasia #ACH 

Tyra Biosciences announced today that company management will present at upcoming investor conferences. More info here: https://bit.ly/4bT32P5

Check out TEAM TYRA in action at today's BCAN Walk to End Bladder Cancer! We will continue to raise awareness in May for Bladder Cancer Awareness month and work "Tyrelessly" to advance next-generation product candidates with the goal to improve patient outcomes and quality of life. #BCAN #bladdercancer

This week during Bladder Cancer Awareness month, we're showing our support for patients and their families as a sponsor of the BCAN 2024 Walk to End Bladder Cancer! We invite you to get involved, lace up your sneakers, and join us in person or online! Check out our team and more details here: https://bit.ly/4boUteM #BCAN #bladdercancer #Bladdersmatter

Tyra Biosciences reported financial results for the quarter ended March 31, 2024, and highlighted recent corporate progress. Learn more here: https://bit.ly/4bmEqxQ

Today, Tyra Biosciences announced the appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to our Board of Directors. Learn more here: https://bit.ly/3UP6DYt

Tyra Biosciences is proud to be an Aspen level sponsor at the 2024 Cholangiocarcinoma Foundation Annual Conference, being held April 17-19, 2024, in Salt Lake City. We look forward to collaborating with industry colleagues, hearing from patients and caregivers, and learning about the newest advancements in research and clinical development. More details can be found here: https://bit.ly/4aNaLNU   #CCAHOPE #cholangiocarcinoma